Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Trading Statement

31 Jul 2007 07:01

Cyprotex PLC31 July 2007 TRADING UPDATE31 July 2007 Cyprotex PLC (the "Company" or "Cyprotex") Progress in line with expectations Progress during the six months to end-June 2007 continued in line with thatintimated in this year's Annual General Meeting (AGM) statement. Revenueperformance for the period was slightly ahead of that seen for the first half of2006, although this was behind expectations detailed by management on the outsetof the year. The Chief Executive Officer's AGM statement detailed the efforts by a group of 'Requisitionists' intent of unseating the present management, which resulted ina highly unnecessary and costly diversion for the company. This was compoundedby the loss of an important client, who made a surprise exit from small moleculeresearch. Although the second-half of this year has started on a stronger note,Cyprotex has yet to regain the momentum it was enjoying at the end of 2006. Theslippage of contract signings and collaborative agreements that has, to date,characterised 2007, however, is shortly expected to pass. Indeed, a verysignificant screening project agreed this month for one of the world's 'Top Ten'pharmaceutical companies serves not only to remind investors that Cyprotex setsglobal standards in its industry, but also of the huge potential for adoption ofits technical capabilities. Management remains confident of both Cyprotex'sbusiness plan and its market opportunity. Based on anticipated workload, Cyprotex presently has sufficient financialresources to service its obligations, whilst continuing to expand its marketingreach and research capabilities during 2007. Although the Board of Directors isnot anticipating the need to seek new external finance, the significant 'cashcushion' the company had this time last year is much reduced. Cyprotex plc's results for the six months to end-June 2007 are expected to bereleased on Thursday, 30th August 2007. For further information: Cyprotex plcRobert Morrisson Atwater, CEORussell Gibbs, CFOTel: +44 (0) 1625 505 100ir@cyprotex.comwww.cyprotex.com Code Securities LimitedCharles Walker, Corporate FinanceTel: +44 (0)20 7776 1200cic@codesecurities.comwww.codesecurities.com Media Enquires: WMC CommunicationsAlex GloverTel: +44 (0)20 7930 9030alex.glover@wmccommunications.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Apr 20164:11 pmRNSForm 8.3 - Cyprotex PLC
7th Apr 20161:42 pmRNSForm 8.3 - Cyprotex
7th Apr 20169:37 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
6th Apr 20169:19 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
5th Apr 20163:10 pmRNSForm 8.3 - Cyprotex PLC
5th Apr 20169:30 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th Apr 201612:36 pmBUSForm 8.3 - Cyprotex Plc
4th Apr 201612:01 pmRNSForm 8.3 - Cyprotex plc
4th Apr 201610:32 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th Apr 201610:31 amPRNForm 8.3 - Cyprotex Plc
1st Apr 20163:58 pmRNSForm 8.3 - Cyprotex Plc
1st Apr 20167:02 amRNSStrategic Review
1st Apr 20167:01 amRNSNotice of General Meeting
1st Apr 20167:00 amRNSFinal Results
31st Mar 201610:58 amRNSLaunch of Advanced 3D Liver Model
29th Mar 20167:00 amRNSChanges to UK reporting framework
9th Mar 20167:00 amRNSLaunch of New Chemical and Cosmetics Testing Guide
10th Feb 20167:00 amRNSStrategic partnering deal with Cytocentrics
21st Jan 20167:00 amRNSExecutive Option Scheme
17th Dec 20159:09 amRNSTrading Update
17th Nov 20157:00 amRNSLaunch of Solution to Predict Preclinical Toxicity
23rd Oct 20157:00 amRNSTrading Update
15th Oct 20157:00 amRNSLaunch of New ADME Guide
13th Oct 20157:00 amRNSPartnership in the EC funded EU-ToxRisk consortium
8th Oct 20157:00 amRNSConversion of Loan Notes, Directors Dealing & TVR
21st Sep 20158:40 amRNSHolding(s) in Company
19th Aug 201512:02 pmRNSHolding(s) in Company
18th Aug 20157:00 amRNSInterim Results 2015
16th Jul 20157:00 amRNSLaunch of new Biosciences division
14th Jul 20157:00 amRNSLaunch of new chemPK workflow solution
10th Jul 201510:32 amRNSHolding(s) in Company - REPLACEMENT
10th Jul 201510:29 amRNSHolding(s) in Company - REPLACEMENT
9th Jul 20151:01 pmRNSHolding(s) in Company
9th Jul 20151:00 pmRNSHolding(s) in Company
17th Jun 201510:26 amRNSResult of AGM
1st Jun 20157:00 amRNSTrading Update
22nd May 20157:00 amRNSPublication of Annual Report & Notice of AGM
6th May 20157:02 amRNSHolding(s) in Company
15th Apr 20157:00 amRNSFinal Results
14th Apr 20157:00 amRNSLaunch of in vitro service using 3D microtissues
31st Mar 20157:00 amRNSLaunch of new laboratory in its US facility
19th Mar 20157:00 amRNSLaunch of Short Time Exposure Service
12th Mar 20157:00 amRNSAppointment of Leader of Drug Transporter Team
22nd Dec 201412:12 pmRNSDirector Dealing
19th Nov 20141:26 pmRNSDirector Dealing 19 November 2014
14th Nov 20143:34 pmRNSDirector Dealing 14 November 2014
14th Nov 20147:00 amRNSTrading Update
13th Nov 20145:17 pmRNSHolding(s) in Company
14th Oct 20147:00 amRNSEnhanced SenCeeTox® technology
13th Oct 20142:14 pmRNSConversion of Loan Notes & TVR (Replacement)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.